A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Abstract

These results suggest that emicizumab prophylaxis with the tested dosing regimen and completion criteria may have a favorable benefit-risk profile in PwAHA.